Fractyl Health(GUTS)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

GUTS Fractyl Health

交易中 07-23 12:22:00 EDT

4.13

+0.14

+3.51%

最高4.13	最低4.02	成交量4.17万
今开4.02	昨收3.99	日振幅2.76%
总市值1.98亿	流通市值7,180万	总股本4,790万
成交额16.93万	换手率0.24%	流通股本1,738万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"GUTS","market":"US","secType":"STK","nameCN":"Fractyl Health","latestPrice":4.13,"timestamp":1721751599974,"preClose":3.99,"halted":0,"volume":41682,"delay":0,"floatShares":17383794,"shares":47896908,"eps":-1.82471,"marketStatus":"交易中","marketStatusCode":2,"change":0.14,"latestTime":"07-23 12:22:00 EDT","open":4.02,"high":4.13,"low":4.0199,"amount":169309.74973440001,"amplitude":0.027594,"askPrice":4.18,"askSize":9,"bidPrice":4.12,"bidSize":203,"shortable":3,"etf":0,"ttmEps":-1.82471,"exchange":"NASDAQ","tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1721764800000},"adr":0,"listingDate":1706850000000,"adjPreClose":3.99,"preHourTrading":{"tag":"盘前","latestPrice":4.01,"preClose":3.99,"latestTime":"09:06 EDT","volume":91,"amount":371.809984,"timestamp":1721740000963},"postHourTrading":{"tag":"盘后","latestPrice":4.05,"preClose":3.99,"latestTime":"19:00 EDT","volume":1355,"amount":5371.33,"timestamp":1721689257233},"volumeRatio":0.498093},"requestUrl":"/m/hq/s/GUTS","defaultTab":"news","newsList":[{"id":"2446537462","title":"Fractyl Health(GUTS.US)GLP-1基因疗法可阻止司美格鲁肽停药反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=2446537462","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446537462?lang=zh_cn&edition=full","pubTime":"2024-06-27 20:58","pubTimestamp":1719493123,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，近日，专注于肥胖和2型糖尿病新方法开发的Fractyl Health在第84届美国糖尿病协会科学会议上口头报告了其临床前GLP-1基因疗法Rejuva的最新数据。Rejuva还能够防止司美格鲁肽停药后的体重和血糖反弹。据了解，Rejuva是Fractyl Health开发的一款基于腺相关病毒的GLP-1胰腺基因疗法项目，旨在实现胰腺中GLP-1的持久生产，用于治疗肥胖和2型糖尿病。研究还调查了单剂Rejuva在司美格鲁肽停药后对DIO小鼠的影响。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1141950.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["GLP","BK4082","GUTS","BK4590","BK4144"],"gpt_icon":0},{"id":"2436193801","title":"Fractyl Health, Inc.2024财年第一财季实现净利润-3.32百万美元，同比增加72.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2436193801","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2436193801?lang=zh_cn&edition=full","pubTime":"2024-05-20 00:06","pubTimestamp":1716134786,"startTime":"0","endTime":"0","summary":"3月31日，Fractyl Health, Inc.公布财报，公告显示公司2024财年第一财季净利润为-3.32百万美元，同比增加72.17%；其中营业收入为33000.00美元，同比增加560.00%，每股基本收益为-0.11美元。从资产负债表来看，Fractyl Health, Inc.总负债79.34百万美元，其中短期债务3.59百万美元，资产负债比为0.03，流动比率为0.10。机构评级：截至2024年3月31日，当前有2家机构对Fractyl Health, Inc.目标价做出预测，其中目标均价为22.00美元，其中最低目标价为18.00美元，最高目标价为26.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240520000630877aafa2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240520000630877aafa2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GUTS"],"gpt_icon":0},{"id":"2424711134","title":"BUZZ-Fractyl Health 第四季度亏损扩大，业绩下滑","url":"https://stock-news.laohu8.com/highlight/detail?id=2424711134","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2424711134?lang=zh_cn&edition=full","pubTime":"2024-04-01 21:02","pubTimestamp":1711976562,"startTime":"0","endTime":"0","summary":" (更新)    4月1日 - ** Fractyl Health   股价盘前下跌约22%至5.80 美元      ** 公司报告第四季度净亏损1920万美元，合每股亏损11.18美元，去年同期亏损1090万美元，合每股亏损7.39美元。** 减肥设备 Revita 的销售和租赁收入 \"微不足道\"，2023 年收入为 10 万美元 - GUTS     ** Revita 已在欧洲获得批准，GUTS 去年已在德国启动了该设备的有限商业试点。** 截至上次收盘，GUTS 自 2 月 2 日上市以来下跌了 46.2","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BUZZ","GUTS","BK4082"],"gpt_icon":0},{"id":"2424792257","title":"BUZZ-Fractyl Health 在 FDA 允许对体重管理设备进行研究后获得收益","url":"https://stock-news.laohu8.com/highlight/detail?id=2424792257","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2424792257?lang=zh_cn&edition=full","pubTime":"2024-04-01 19:12","pubTimestamp":1711969935,"startTime":"0","endTime":"0","summary":"    4月1日 - ** Fractyl Health   股价在盘前交易中上涨 5.3% 至 7.79 美元 ** 该公司称，美国卫生监管机构已经批准了对其研究性设备Revita的减肥效果进行研究的申请。** Revita旨在通过手术重塑小肠的十二指肠内壁，十二指肠内壁接收来自胃部的食物并开始吸收营养。** 联合研究公司称，Remain-1 研究将测试 Revita 与假治疗的对比，测试对象是使用替扎帕肽后体重至少减轻 15%的患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1804176565.USD","LU0061475181.USD","LU0122379950.USD","BK4588","LU0820561818.USD","IE00BJJMRZ35.SGD","LU0417517546.SGD","LU0640476718.USD","LU0238689110.USD","LU2237438978.USD","LU1551013342.USD","BK4581","IE00B1BXHZ80.USD","LU0882574055.USD","LU2468319806.SGD","LU0198837287.USD","BK4534","LU0689472784.USD","LU1280957306.USD","BUZZ","SG9999001176.USD","LU1988902786.USD","LU0320765059.SGD","LU1814569148.SGD","LU2237443549.SGD","LU0256863811.USD","LU1023059063.AUD","LU2491050071.SGD","LU2491050154.USD","IE00B2B36J28.USD","BK4007","LU1712237335.SGD","IE0009355771.USD","LU1623119135.USD","GUTS","BK4533","LU2491049909.HKD","LU0058720904.USD","BK4082","LLY","LU1267930730.SGD","LU2237443382.USD","IE0002141913.USD","LU0466842654.USD","IE00BJT1NW94.SGD","LU0672654240.SGD","LU2264538146.SGD","IE00BFTCPJ56.SGD","LU0114720955.EUR","LU2602419157.SGD"],"gpt_icon":0},{"id":"2418323135","title":"BUZZ-Fractyl 在小鼠中进行的肥胖症和糖尿病治疗试验前景看好","url":"https://stock-news.laohu8.com/highlight/detail?id=2418323135","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2418323135?lang=zh_cn&edition=full","pubTime":"2024-03-12 21:26","pubTimestamp":1710249963,"startTime":"0","endTime":"0","summary":"    3月12日 - ** Fractyl Health   股价盘前上涨18.5%至9.40美元** 该公司称， ，其治疗糖尿病和肥胖症的实验性基因疗法RJVA-001在4周的小鼠实验中实现了高达50%的血糖降低率和11%的体重减轻率，而semaglutide则实现了32%的血糖降低率和2%的体重减轻率。** 公司预计该疗法将于 2024 年获得 FDA 批准进行临床试验，并于 2025 年启动人体临床研究。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BUZZ","GUTS","BK4082"],"gpt_icon":0},{"id":"2414638669","title":"BUZZ-随着 IPO 研究平静期的结束，Fractyl Health 跃升","url":"https://stock-news.laohu8.com/highlight/detail?id=2414638669","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2414638669?lang=zh_cn&edition=full","pubTime":"2024-02-28 02:25","pubTimestamp":1709058349,"startTime":"0","endTime":"0","summary":"    2月27日 - ** 随着 IPO 研究平静期的结束，Fractyl Health   股价在下午交易中上涨 10%，至 8.36 美元。** 券商BofA Global Research给予这家药品开发商 \"买入 \"评级。** BofA、摩根士丹利和 Evercore ISI 是此次 IPO 的承销商  ** BofA 表示，该公司的 2 型糖尿病治疗设备 Revita 正在进行关键测试，第四季度将公布初步数据，这将有助于该产品在数十亿美元的市场上获得批准。** 自 2 月 2 日上市以来股价下跌了 44.2","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","GUTS","BUZZ"],"gpt_icon":0},{"id":"2408131185","title":"2024年破发第一股：减肥药大时代的“风口”与“疯口”","url":"https://stock-news.laohu8.com/highlight/detail?id=2408131185","media":"钛媒体APP","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2408131185?lang=zh_cn&edition=full","pubTime":"2024-02-04 17:07","pubTimestamp":1707037669,"startTime":"0","endTime":"0","summary":"2023年7月，礼来公司的SURMOUNT试验结果，Tirzepatide同样显示出类似的“反弹效应”。这意味着，减肥药对于社会来说，存在较大的经济负担。去年10月4日，Fractyl Health在欧洲糖尿病研究协会年会上，公布了Rejuva临床前研究结果。结果发现，GLP-1受体激动剂组的动物，体重基本恢复了正常；而GLP-1 PGTx药物组的动物，仍保持28天接近的降重水准。04总结虽然减重故事完美，但Fractyl Health并没有上演奇迹，反而成为2024年生物科技领域上市首日破发第一股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240204171840876d6bbf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240204171840876d6bbf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GUTS"],"gpt_icon":0},{"id":"2408612284","title":"Fractyl Health 在美国的首次公开募股价格低于区间，融资 1.1 亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2408612284","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2408612284?lang=zh_cn&edition=full","pubTime":"2024-02-02 10:35","pubTimestamp":1706841334,"startTime":"0","endTime":"0","summary":"    路透2月2日 - 肥胖症和糖尿病药物开发商 Fractyl Health 周四将其美国首次公开募股 定价低于指示区间，以筹集 1.1 亿美元。Fractyl Health将于周五在纳斯达克上市，交易代码为 \"GUTS\"。在经历了两年的枯竭期后，美国的首次公开募股有望在2024年反弹，因为人们对这个世界最大经济体软着陆的信心更加坚定。上个月，医疗保健公司CG Oncology   和KKR支持的BrightSpring Health Services   的首次公开募股结果截然不同，表明投资者仍持谨慎态度。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2264538146.SGD","LU0689472784.USD","LU2602419157.SGD","SG9999001176.USD","IE00BFTCPJ56.SGD","BK4534","IE00BJT1NW94.SGD","LU0672654240.SGD","BK4581","LU1988902786.USD","LU0061475181.USD","LU2237438978.USD","LU1814569148.SGD","LLY","LU1057294990.SGD","BK4585","SG9999014898.SGD","LU0640476718.USD","LU0820561818.USD","LU0109391861.USD","LU0456855351.SGD","LU0289739699.SGD","LU1064131342.USD","LU1551013425.SGD","LU0198837287.USD","LU0058720904.USD","LU0122379950.USD","BK4533","SG9999014880.SGD","LU0320765059.SGD","BK4588","LU0466842654.USD","IE00BJJMRZ35.SGD","SG9999013999.USD","LU0256863811.USD","LU0882574055.USD","GUTS","LU0417517546.SGD","BTSG","LU1023059063.AUD","LU1280957306.USD","IE00B2B36J28.USD","LU1551013342.USD","SG9999001176.SGD","LU0708995401.HKD","LU1267930730.SGD","IE0009355771.USD","CGON","GB00BDT5M118.USD","LU2468319806.SGD"],"gpt_icon":0},{"id":"2407309426","title":"糖尿病及肥胖症疗法研发公司Fractyl Health(GUTS.US)IPO定价14-16美元 拟筹资1.1亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2407309426","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2407309426?lang=zh_cn&edition=full","pubTime":"2024-01-31 15:55","pubTimestamp":1706687721,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，糖尿病及肥胖症疗法研发公司Fractyl Health宣布了其首次公开募股条款。该公司计划以每股14-16美元的价格发行730万股股票，筹资1.1亿美元。据悉，Fractyl Health专注于开发治疗代谢性疾病的新疗法。该公司的主要候选产品是Revita DMR系统，这是一种门诊程序治疗，旨在持久改善十二指肠功能障碍。目前，Revita已获得欧洲批准，用于治疗控制不良的2型糖尿病患者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1065623.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["GUTS"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.fractyl.com","stockEarnings":[{"period":"1week","weight":-0.1133},{"period":"1month","weight":-0.1153},{"period":"3month","weight":-0.3908},{"period":"6month","weight":-0.734},{"period":"ytd","weight":-0.734}],"compareEarnings":[{"period":"1week","weight":-0.0123},{"period":"1month","weight":0.0186},{"period":"3month","weight":0.0969},{"period":"6month","weight":0.1427},{"period":"1year","weight":0.2266},{"period":"ytd","weight":0.1669}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Fractyl Health, Inc.于2010年8月30日根据特拉华州法律注册成立。该公司是一家代谢治疗公司，专注于开拓治疗代谢性疾病的新方法，包括2型糖尿病和肥胖症。根据疾病控制中心和国际糖尿病联合会的数据，美国大约有1亿人患有前驱糖尿病和肥胖症，另有2500万人患有糖尿病，正在接受药物治疗。他们的目标是开发持久的疾病改善疗法，旨在通过针对T2D和肥胖的器官水平根源，提供代谢健康的长期维持，而不需要终身治疗。","exchange":"NASDAQ","name":"Fractyl Health","nameEN":"Fractyl Health"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Fractyl Health(GUTS)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Fractyl Health(GUTS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Fractyl Health,GUTS,Fractyl Health股票,Fractyl Health股票老虎,Fractyl Health股票老虎国际,Fractyl Health行情,Fractyl Health股票行情,Fractyl Health股价,Fractyl Health股市,Fractyl Health股票价格,Fractyl Health股票交易,Fractyl Health股票购买,Fractyl Health股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Fractyl Health(GUTS)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Fractyl Health(GUTS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}